凝血因子Xa抑制剂凝血检测的事实与假象 - Suppr

Suppr

超能文献

Facts and artefacts of coagulation assays for factor Xa inhibitors.

作者信息

Haas Sylvia

出版信息

Thromb Haemost. 2010 Apr;103(4):686-8. doi: 10.1160/TH10-01-0080. Epub 2010 Feb 19.

DOI:10.1160/TH10-01-0080

PMID:20174751

Abstract

摘要

相似文献

Facts and artefacts of coagulation assays for factor Xa inhibitors.凝血因子Xa抑制剂凝血检测的事实与假象

Thromb Haemost. 2010 Apr;103(4):686-8. doi: 10.1160/TH10-01-0080. Epub 2010 Feb 19.

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.评估用于检测利伐沙班（一种口服、直接的 Xa 因子抑制剂）的实验室检测方法。

Thromb Haemost. 2010 Apr;103(4):815-25. doi: 10.1160/TH09-03-0176. Epub 2010 Feb 2.

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.一种经过优化的快速显色测定法，用于特异性检测血浆中直接Xa因子抑制剂（利伐沙班）。

Thromb Haemost. 2010 Nov;104(5):1078-9. doi: 10.1160/TH10-03-0204. Epub 2010 Aug 30.

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.直接因子 Xa 抑制剂的临床实验室检测：抗 Xa 测定优于凝血酶原时间测定。

Thromb Haemost. 2010 Dec;104(6):1263-71. doi: 10.1160/TH10-05-0328. Epub 2010 Oct 26.

Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.利伐沙班对一期法和发色底物法检测因子VIII:C的干扰

Thromb Haemost. 2011 Nov;106(5):990-2. doi: 10.1160/TH11-04-0277. Epub 2011 Sep 8.

Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.在利伐沙班存在的情况下凝血因子活性测定方法的优化。

Thromb Res. 2012 Jan;129(1):101-3. doi: 10.1016/j.thromres.2011.09.004. Epub 2011 Oct 13.

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.急性冠状动脉综合征后口服、直接因子 Xa 抑制剂阿哌沙班对凝血活性生物标志物的影响。

Thromb Haemost. 2010 Nov;104(5):976-83. doi: 10.1160/TH10-04-0247. Epub 2010 Aug 30.

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.利伐沙班校准的国际标准化比值有使利伐沙班治疗患者的凝血酶原时间结果标准化的潜力：一项体外研究的结果

J Thromb Haemost. 2011 Jan;9(1):226-8. doi: 10.1111/j.1538-7836.2010.04106.x.

[Rivaroxaban: mode of action].[利伐沙班：作用机制]

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S9-15. doi: 10.1016/S0750-7658(08)75141-4.

Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.实验室检测评估阿哌沙班血药浓度：三种抗 Xa 检测方法的适用性。一项多中心法国 GEHT 研究。

Thromb Haemost. 2014 Feb;111(2):240-8. doi: 10.1160/TH13-06-0470. Epub 2013 Oct 31.

引用本文的文献

The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.服用阿哌沙班或利伐沙班的患者在射频消融（RFA）期间肝素的抗凝作用。

J Interv Card Electrophysiol. 2017 Sep;49(3):237-244. doi: 10.1007/s10840-017-0274-2. Epub 2017 Jul 22.

Anticoagulant therapy in pediatrics.儿科抗凝治疗

J Basic Clin Pharm. 2014 Mar;5(2):27-33. doi: 10.4103/0976-0105.134947.

Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.血栓弹力描记术可检测利伐沙班对脑卒中患者的抗凝效果。

Stroke. 2014 Mar;45(3):880-3. doi: 10.1161/STROKEAHA.113.004016. Epub 2014 Jan 14.

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.一项关于依度沙班（一种口服 Xa 因子抑制剂）在从华法林转换后的安全性、药代动力学和药效学的随机试验。

Br J Clin Pharmacol. 2013 Apr;75(4):966-78. doi: 10.1111/j.1365-2125.2012.04409.x.

Current and future management of pediatric venous thromboembolism.小儿静脉血栓栓塞症的当前和未来管理。

Am J Hematol. 2012 May;87 Suppl 1(0 1):S68-74. doi: 10.1002/ajh.23131. Epub 2012 Feb 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验